全关节置换术后清创、抗生素与假体保留后应用抑制性抗生素治疗耐受良好且不诱导耐药:一项多中心研究
该多中心研究纳入2015至2020年间两个学术医学中心因急性假体周围关节感染行全关节置换术后清创、抗生素与假体保留(DAIR)的115例患者,评估抑制性抗生素治疗(SAT)的不良反应、因感染再手术及抗生素耐药情况。结果显示TKA与THA的DAIR患者ADR/不耐受率分别为11.1%和16.3%,SAT中位持续11个月,未出现因SAT导致的抗生素耐药;作者建议考虑SAT,但使用甲氧苄啶/磺胺甲噁唑需谨慎。
要点
- TKA与THA的DAIR患者SAT不良反应/不耐受率分别为11.1%和16.3%。
- TKA DAIR后使用甲氧苄啶/磺胺甲噁唑(P=0.0014)或联合抗生素方案(P=0.0169)者ADR/不耐受风险增加。
- 平均2.8年随访中TKA与THA的无再手术生存率分别为83.3%和65.1%,两组无差异(P=0.5900);SAT未诱导抗生素耐药。
核心结论
- 作者认为可考虑在全关节置换术后DAIR后应用SAT,因无再手术生存改善且安全性良好。
- 延长SAT未诱导抗生素耐药。
- 因ADR/不耐受可能性增加,使用甲氧苄啶/磺胺甲噁唑需谨慎。
研究设计与样本
- 多中心研究,纳入两个学术医学中心2015至2020年因急性假体周围关节感染行全膝关节置换或全髋关节置换DAIR的患者115例。
- 收集患者人口学、感染病原体、抗生素、ADR/不耐受、再手术及抗生素耐药数据,SAT中位持续11个月。
- 采用逐步多因素logistic回归识别与结局显著相关的协变量。
主要发现
- TKA与THA的DAIR患者分别有11.1%和16.3%出现SAT的ADR/不耐受。
- TKA DAIR后使用甲氧苄啶/磺胺甲噁唑者ADR/不耐受风险增加(P=0.0014),使用联合抗生素方案者风险亦增加(P=0.0169)。
- 平均2.8年随访时,TKA与THA的无再手术生存率分别为83.3%和65.1%,两组无差异(P=0.5900)。
- TKA金黄色葡萄球菌感染因感染再手术风险更高(P=0.0004),SAT持续时间延长则风险降低(P<0.0450)。
- SAT的最佳持续时间接近2年;未出现因SAT导致的抗生素耐药病例。
关键数值与推荐
- TKA DAIR患者ADR/不耐受率11.1%,THA DAIR患者16.3%。
- TKA DAIR后使用甲氧苄啶/磺胺甲噁唑P=0.0014,联合抗生素治疗P=0.0169,均与ADR/不耐受风险增加相关。
- 平均2.8年随访无再手术生存率TKA 83.3% vs THA 65.1%(P=0.5900)。
- TKA金黄色葡萄球菌感染因感染再手术风险P=0.0004,SAT持续时间延长P<0.0450。
- SAT最佳持续时间接近2年。
临床怎么用
- 作者认为可考虑在全关节置换术后DAIR后应用SAT,因无再手术生存改善且安全性良好。
- 作者建议因ADR/不耐受可能性增加,使用甲氧苄啶/磺胺甲噁唑需谨慎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Suppressive antibiotic therapy (SAT) after total joint arthroplasty (TJA) debridement, antibiotics, and implant retention (DAIR) maximizes reoperation-free survival. We evaluated SAT after DAIR of acutely infected primary TJA regarding: 1) adverse drug reaction (ADR)/intolerance; 2) reoperation for infection; and 3) antibiotic resistance. METHODS: Patients who underwent total knee arthroplasty (TKA) or total hip arthroplasty (THA) DAIR for acute periprosthetic joint infection at two academic medical centers from 2015 to 2020 were identified (n = 115). Data were collected on patient demographics, infecting organisms, antibiotics, ADR/intolerances, reoperations, and antibiotic resistances. Median SAT duration was 11 months. Stepwise multivariate logistic regressions were used to identify covariates significantly associated with outcomes of interest. RESULTS: There were 11.1 and 16.3% of TKA and THA DAIR patients, respectively, who had ADR/intolerance to SAT. Patients prescribed trimethoprim/sulfamethoxazole (P = .0014) or combination antibiotic therapy (P = .0169) after TKA DAIR had increased risk of ADR/intolerance. There was no difference in reoperation-free survival between TKA (83.3%) and THA (65.1%) DAIR (P = .5900) at mean 2.8-year follow-up. Risk of reoperation for infection was higher among TKA Staphylococcus aureus infections (P = .0004) and lower with increased SAT duration (P < .0450). The optimal duration of SAT was nearly 2 years. No cases of antibiotic resistance developed due to SAT. CONCLUSIONS: Consider SAT after TJA DAIR due to improved reoperation-free survival and favorable safety profile. Prolonged SAT did not induce antibiotic resistance. Use trimethoprim/sulfamethoxazole with caution because of the increased likelihood of ADR/intolerance. LEVEL OF EVIDENCE: Therapeutic Level III.
引用
- Nandi S, Doub JB, De Palma BJ, et al. Suppressive Antibiotic Therapy After Debridement, Antibiotics, and Implant Retention is Well-Tolerated Without Inducing Resistance: A Multicenter Study. J Arthroplasty. 2023. PMID: 37717831. doi:10.1016/j.arth.2023.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。